Skip to main content
. 2018 Jun 12;8:185. doi: 10.3389/fonc.2018.00185

Figure 2.

Figure 2

Aryl hydrocarbon receptor nuclear translocator-like protein 1 (BMAL1) expression positively correlates with antitumor immunity in metastatic melanomas. (A) Gene Set Enrichment Analysis (GSEA) using genes ranked according to the Spearman’s correlation coefficient between their expression and the expression of BMAL1 in The Cancer Genome Atlas (TCGA) metastatic melanomas (n = 340). Normalized enrichment scores (NES) and P-values corrected by false discovery rate (FDR) were calculated using GSEA v3.0 and Reactome pathways. Only significantly enriched pathways (adjusted P < 0.05) are shown. (B) Spearman’s correlation coefficient between the expression of BMAL1 and immune cells markers in TCGA metastatic melanomas. P-values were corrected by FDR. (C) Association between BMAL1 expression (pretreatment biopsies) and clinical benefit of melanoma patients from anti-PD1 immunotherapy (nivolumab). RNAseq data and treatment response information were obtained from Ref. (42). Comparisons were performed using the Chi-square test. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.